Alnylam Pharmaceuticals, Inc. (ALNY)
362.71
-7.29
(-1.97%)
USD |
NASDAQ |
Jan 23, 11:54
Alnylam Pharmaceuticals Cash from Investing (Quarterly): 501.11M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Insmed, Inc. | -762.23M |
| Pfizer Inc. | -2.43B |
| Biogen, Inc. | -35.10M |
| Bristol Myers Squibb Co. | -1.702B |
| Vertex Pharmaceuticals, Inc. | -117.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 325.11M |
| Cash from Financing (Quarterly) | -448.35M |
| Free Cash Flow | 221.36M |
| Free Cash Flow Per Share (Quarterly) | 2.279 |
| Free Cash Flow to Equity (Quarterly) | 279.39M |
| Free Cash Flow to Firm (Quarterly) | 359.62M |
| Free Cash Flow Yield | 0.46% |